Blue Jet Healthcare's share price was trading 3.55 per cent lower at ₹704.8 per share compared to previous day's close of ₹730 on the NSE
Thus far in September, the stock price of Laurus Labs has rallied 6 per cent, as compared to a 1.5 per cent rise in the BSE Sensex and BSE Healthcare index
Around 11:20 PM, Glenmark Pharmaceuticals shares continued to trade higher, up 3.05 per cent at ₹2,051.40 per share. In comparison, BSE Sensex was trading 0.25 per cent lower at 80,518.51 levels.
The inspection covered various aspects of operations including drug substance manufacturing units, analytical quality control laboratories, microbiology laboratories, and warehouses
According to Nuvama analysts Shrikant Akolkar, Aashita Jain and Gaurav Lakhotia, the company is positioned for robust growth over the medium-term, driven by capacity expansion and product additions.
Drugmaker Lupin said it has received the USFDA's approval for Risperidone for extended-release injectable suspension
Post-listing, the Anlon Healthcare stock was trading at ₹91.5, up 0.55 per cent from the listing price on the BSE
Dr Agarwal's Eye Hospital shares fell 17.7 per cent, while Dr Agarwal's Health Care slid 6.83 per cent on the merger announcement
Thus far in August 2025, Sun Pharma has underperformed the market by falling 8 per cent, as compared to a 1 per cent decline in the BSE Sensex
SMS Pharmaceuticals shares rose 10 per cent after it received an Establishment Inspection Report with a No Action Indicated from the USFDA
The upward movement in the pharmaceutical company's stock price followed an announcement regarding the company's Limbasi API facility
The upward movement in Marksans Pharma's share price came after the company announced that its wholly owned subsidiary, Relonchem in the UK, had received marketing authorisation for its products
Shilpa Medicare shares rose after the company announced a 1:1 bonus issue, with the Board approving the proposal in its meeting on August 13, 2025.
Pfizer's share price gained today after the company announced the launch of its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India.
The rally in the share price of Sai Life Sciences comes after the company swung back to report a profit of ₹60 crore in Q1FY26
Divi's Laboratories reported a 14 per cent year-on-year jump in revenue at ₹2,410 crore in Q1FY26, compared to ₹2,118 crore in the year-ago period
Alembic Pharma fell around 3.5 per cent to hit an intraday low of ₹913 on the NSE, after the company reported its June 2025 quarter results
The pharma company's profit after tax (PAT) for the quarter ended June 30, 2025, stood at ₹215 crore, up 50 per cent from ₹143 crore reported in the corresponding quarter of the previous fiscal year.
Aurobindo Pharma's net profit fell 10.2 per cent Y-o-Y to ₹824 crore in Q1FY26, as against ₹918 crore in the same quarter last year
Pharma stocks came under pressure after President Trump announced a 25 per cent tariff rate for Indian exports to the US